Response rates to anti–PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase
Importance In June 2020, the US Food and Drug Administration approved the anti–
programmed cell death 1 drug pembrolizumab for patients with malignant solid tumors of
any histologic type with high tumor mutational burden (TMB;≥ 10 mutations per megabase).
The predictive value of this universal cutoff for high TMB is not well understood. Objective To
examine the performance of a universal definition of high TMB in an independent cohort of
patients with solid tumors treated with immune checkpoint inhibitors. Design, Setting, and …
programmed cell death 1 drug pembrolizumab for patients with malignant solid tumors of
any histologic type with high tumor mutational burden (TMB;≥ 10 mutations per megabase).
The predictive value of this universal cutoff for high TMB is not well understood. Objective To
examine the performance of a universal definition of high TMB in an independent cohort of
patients with solid tumors treated with immune checkpoint inhibitors. Design, Setting, and …
